ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics, and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced the construction and qualification of a new Class
The creation of artificial embryos has moved a step forward after an international team of researchers used mouse stem cells to produce artificial embryo-like structures capable of ‘gastrulation’, a key step in the life of any embryo.
Neovii pharmaceuticals AG of Rapperswil, Switzerland and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October.
A new class of clay nanoparticles that can direct stem cells to become bone or cartilage cells. Human stem cells have shown potential in medicine as they can transform into various specialized cell types such as bone and cartilage cells. The current approach to obtain such specialized cells is to subject stem cells to specialized instructive protein molecules known as growth factors. However, use of growth factors in the human body can generate harmful effects including unwanted tissue growth, such as a tumor.
